By limiting the amount of oxidative damage to LDL.

Pashkow said that? the recent problems with Pfizer aspirin highlight the impact of a pipeline late non-admission to the impending patent expiry of the current market-leading therapy combined. Antiplatelet treatment, especially aspirin and aspirin in combination with other antiplatelet agents represent the ‘second great wave ‘of preventive treatment after a heart attack. In combination, they reduce the risk of future heart attacks and strokes by about 30 percent over a period of one year. – However, if a significant segment of the population ‘resistant’to therapy with platelet inhibitors, and remain relatively unprotected. Stronger antiplatelet treatment, or increased doses of aspirin, the risk of bleeding. ‘This wave of treatments,’said Pashkow ‘may also reaches its climax.

Models. Is a potent inhibitor of oxidation of the cell membrane modelA just-released study by Dr. R Preston Mason and colleagues at Elucida research has found that astaxanthin, a relatively unknown carotenoid found in nature, promising, as demonstrated viable framework for a new treatment for cardiovascular disease to be treated on its exceptional antioxidant properties in membrane models.Some in part on. Grants from the National Institutes of Health , and which Michael J. Fox Foundation The donor had been no difference to planning and execution of this study, the collection, analysis of and interpretation of data;. And in the preparation, review or approval the manuscript.

####on the authorsthe trial was conducted primarily by the Mayo Clinic researchers, bioinformatic support for out of Spyridon Papapetropoulos, and Lina Shehadah, the Miller School of Medicine, University of Miami.